AI May Help With MRI Interpretation During Prostate Cancer Detection

Commentary
Video

Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.

CancerNetwork® spoke with Wayne G. Brisbane, MD during Prostate Cancer Awareness Month 2023 about how implementing artificial intelligence (AI) into the clinical landscape may help in detecting prostate cancer more effectively in patients who need to undergo an MRI.

Brisbane, an assistant professor of urology at the University of California, Los Angeles (UCLA) Health, discussed his experiences with a machine learning algorithm called Unfold AI in patients with elevated prostate specific antigen (PSA) levels who need to proceed to an MRI, which his practice often employs in prostate cancer detection. He described how the AI program may be able to elucidate signs of disease in an MRI that are not typically perceptible to the human eye, thereby giving information on how best to manage the tumor.

Transcript:

AI is being used in prostate cancer in a couple of different ways, mostly on the diagnostic side. I use it in men who come in with an elevated PSA, which is our best and most reliable way to screen men for prostate cancer. If you have an elevated PSA—I tell men it’s like a thermometer for your prostate; it goes up for all kinds of reasons—maybe it’s something in the prostate that could just be size or some inflammation, but it could be prostate cancer. [Therefore], we need to figure out exactly what that is for men.

We’re using AI to interpret the MRIs. After a PSA elevation, oftentimes men will get an MRI or a biomarker [assessment]—in my [practice], we use MRI quite a bit. We will use the MRIs, and if it doesn’t look like there’s anything to the naked eye, we’ll have an AI go and take a second look at it. [From there] if there is a lesion on the MRI and we do a biopsy. We’re using a machine learning algorithm called Unfold AI that carefully predicts the location and extent of the tumor. We use that to help us perform treatments.

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Sean Dineen, MD, highlights the removal of abdominal wall lesions and other surgical strategies that may help manage symptoms in patients with cancer.
Related Content